{"entity":{"id":"mcarthur-grant","kind":"person","name":"Grant McArthur","aka":[],"tldr":"A melanoma pioneer who led the vemurafenib and cobimetinib trials and now heads Victoria's cancer alliance.","summary":"Grant McArthur is Executive Director of the Victorian Comprehensive Cancer Centre Alliance and a melanoma medical oncologist at the Peter MacCallum Cancer Centre in Melbourne. He was a principal investigator for BRIM-3 and coBRIM, the trials that established BRAF inhibition with vemurafenib and combined BRAF and MEK inhibition with cobimetinib in melanoma. His publications include the extended follow-up of vemurafenib in BRAF V600E and V600K mutation-positive melanoma from BRIM-3. He has led translational programmes on resistance and on combining targeted therapy with immunotherapy, and now heads Victoria's cancer alliance.","asOf":"2026-09-08","links":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=McArthur%20GA%5BAuthor%5D%20melanoma"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":["braf"],"drugs":["vemurafenib","cobimetinib"],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Director, Victorian Comprehensive Cancer Centre Alliance; melanoma medical oncologist, Peter Mac","institutionId":"peter-mac","specialisms":["Melanoma","BRAF and MEK inhibitors","Immunotherapy","Translational research"],"profiles":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=McArthur%20GA%5BAuthor%5D%20melanoma"}],"papers":[{"title":"Safety and efficacy of vemurafenib in BRAF V600E and V600K mutation-positive melanoma (BRIM-3): extended follow-up","journal":"Lancet Oncology","year":2014,"doi":"10.1016/S1470-2045(14)70012-9"},{"title":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2407417","doi":"10.1056/NEJMoa2407417"}],"orcid":"0000-0001-8908-6071"},"route":"/people/mcarthur-grant/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"target":[{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/"}],"drug":[{"id":"cobimetinib","kind":"drug","name":"Cobimetinib","route":"/drugs/cobimetinib/"},{"id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/"}],"institution":[{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/"}],"paper":[{"id":"paper-checkmate-067-10-year-nejm-2025","kind":"paper","name":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","route":"/key-papers/paper-checkmate-067-10-year-nejm-2025/"}]}}